Stifel reiterates Buy on IPG Photonics stock after acquisition deal

Stifel reiterates Buy on IPG Photonics stock after acquisition deal

U.S. futures slide with AI worries in focus; Netflix disappoints Investing.com - Stifel reiterated a Buy rating and $125.00 price target on IPG Photonics (NASDAQ:IPGP) following the company’s announcement of an acquisition in the medical sector. The stock currently trades at $103.36, up 39% over the past year, though InvestingPro analysis suggests the shares are overvalued relative to its Fair Value estimate. IPG Photonics entered into a binding offer to acquire Lumibird Medical, the ophthalmology-focused medical division of Lumibird SA, for €300 million in cash at closing on a cash-free, debt-free basis.

The deal includes a contingent earnout of up to €50 million, representing 15.9 times fiscal year 2025 adjusted EBITDA. The acquisition adds €112.2 million of medical revenue and roughly triples IPG Photonics’ medical business to approximately $204 million on a pro forma basis. The combined medical platform spans ophthalmology, urology, and dermatology.

The deal lifts Advanced Solutions to approximately 26% of pro forma sales from 16% and expands the company’s addressable market by roughly $1 billion. IPG Photonics has more than $800 million of cash and no debt to fund the transaction. According to InvestingPro, the company holds more cash than debt on its balance sheet and maintains a robust current ratio of 5.8, underscoring its strong financial flexibility.

This is one of several key insights available in the comprehensive Pro Research Report, which covers over 1,400 US equities with expert analysis and actionable intelligence. Stifel views the deal positively and notes it aligns with management’s strategy of pursuing complementary bolt-on acquisitions in the $50 million to $200 million revenue range, with medical as a priority vertical. In other recent news, IPG Photonics Corporation reported a strong financial performance for the first quarter of 2026, surpassing both earnings and revenue forecasts.

The company achieved an earnings per share of $0.29, exceeding the projected $0.27, and reported revenue of $265.5 million, which was above the expected $256.45 million. Additionally, IPG Photonics announced a binding offer to acquire Lumibird Medical for €300 million on a cash-free, debt-free basis, with a contingent earnout of up to €50 million based on future performance metrics. This acquisition will be funded with cash on hand.

Needham upgraded IPG Photonics to a Buy rating from Hold, citing revenue growth, and set a price target of $110.00. Stifel reiterated a Buy rating and a $125.00 price target, following meetings with company management that outlined a multi-year margin recovery strategy. In other developments, IPG Photonics’ Chief Financial Officer, Timothy PV Mammen, sold 9,975 shares of common stock in two separate transactions.

These transactions were executed at weighted average prices of $119.60 and $120.37 per share. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.